H. Thomas Watkins is the CEO of Human Genome Sciences Inc. HGS exists to place new therapies into the hands of those battling serious disease. On March 9, 2011, the FDA approved BENLYSTA, a specialized drug to treat Lupus.

He talks about leadership and operational challenges of becoming a fully commercial biopharmaceutical company.

Read and Enjoy!